|G.F.Mersons Limited, Ethicon Suture Laboratories|
|Industry||Surgical systems and instruments|
|Founder||George F. Merson|
|Headquarters||Somerville, New Jersey and Cincinnati, Ohio|
|Michael Del Prado (chairman)|
|Products||Prolene, Monocryl, Vicryl, Ethilon, Gynecare|
|Revenue||$4.87 billion (sales) (2011)|
Number of employees
|Parent||Johnson & Johnson|
Ethicon, Inc. is a subsidiary of Johnson & Johnson. It was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line.
Ethicon has manufactured surgical sutures and wound closure devices since 1887. After World War II, Ethicon’s market share in surgical sutures rose from 15% to 70% worldwide. In the United States, the market share is approximately 80%.
Ethicon conducts business in 52 countries.
In 1915, George F. Merson opened a facility in Edinburgh for the manufacturing, packaging and sterilising of catgut, silk and nylon sutures. Johnson & Johnson acquired Mr. Merson’s company in 1947, and this was renamed Ethicon Suture Laboratories. In 1953 this became Ethicon Inc.
In 1992, Ethicon was restructured, and Ethicon Endo-Surgery became a separate corporate entity.
During the 1990s, Ethicon diversified into new and advanced products and technologies and formed four different companies under the Ethicon umbrella, each of which specialize in different products.
In November 2008, the wound management business was sold to One Equity Partners and became Systagenix Wound Management Limited.
Gynecare Prolift controversy
Much controversy surrounds Ethicon's transvaginal meshes used on patients with female genital prolapse.
Of these meshes the most important, Ethicon’s Gynecare Prolift, was introduced in March 2005. Ethicon's parent company Johnson & Johnson utilized the FDA’s 501(k) clearance method, which allows a product to be sold without official FDA approval if it is based on another already approved product. However, in 2008, the FDA issued a Public Health Notification regarding reports of serious complications associated with transvaginal mesh devices. This further escalated when, in 2011, the agency received more than 1,000 adverse effect reports from surgical mesh manufacturers. The FDA decided to order Ethicon and other transvaginal mesh manufacturers to cease production until extensive testing and research on each of vaginal mesh device was conducted. In June 2012, following the FDA’s order for additional testing, Johnson & Johnson permanently removed all Prolift products from the market.
In one court case reported by Reuters, the plaintiff, Dianne Bellew, on whom the product had been implanted in 2009, said she was never warned about how the device could contract and erode, causing pain and scarring.
Products and brands
PDS, Nurolon, Mersilene, Dermabond, Silk, Ethibond
- Prolene, Monocryl, Vicryl, and Ethilon
- Gynecare: women's health products.
- Surgical stapling products.
- Energy-based products.
- Endoscopic surgical products.
- Lance Williams "How suture maker kept lid on infection suits: Despite recall, Ethicon said product was harmless" San Francisco Examiner February 22, 1999
- recall enforcement, U.S. Food and Drug Administration
- "Locations around the world". www.ethicon.com. Ethicon U.S. Retrieved 25 January 2016.
- Perriello, Brad (22 May 2014). "J&J's pipeline includes 30 'major' medical devices and a surgical robot – MassDevice". MassDevice. Retrieved 25 January 2016.
- "Management's Discussion and Analysis of Results of Operations and Financial Condition" (PDF). Johnson & Johnson. 2011. p. 29. Retrieved 25 January 2016.
- "ETHICON History". www.ethiconproducts.co.uk. Retrieved 25 January 2016.
- "A history of advancing surgery". www.ethicon.com. Ethicon U.S., LLC. Retrieved 25 January 2016.
- Arnold, Matthew (8 May 2013). "J&J consolidates, rebrands Ethicon units". Medical Marketing & Media.